Sarah Teichmann, head of cellular genetics at the Wellcome Sanger Institute, reflects on the dawn of the single-cell genomics era and a pivotal decision that changed the course of her career.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.A.T. is a scientific advisory board member of ForeSite Labs, Qiagen and Element Biosciences, and a co-founder and equity holder of TransitionBio and EnsoCell Therapeutics.
Rights and permissions
About this article
Cite this article
Teichmann, S.A. Changing course at the dawn of a genomics revolution. Nat Cell Biol 26, 172 (2024). https://doi.org/10.1038/s41556-023-01301-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-023-01301-x
